de Wilde, G. | bioRxiv Science

bioRxiv2026

AID Shapes Proliferation and Cell-of-Origin-associated Transcriptional Programs in Diffuse Large B-cell Lymphoma

Activation-induced cytidine deaminase (AID), which is essential for antibody diversification, exhibits elevated expression in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL). Here, we demonstrate that AID modulates transcriptional programs linked to cell cycle progression, proliferation, and DLBCL subtype identity. AID loss in ABC-type DLBCL cell lines negatively impacts MYC and E2F pathway activity, while AID re-expression restores activity, establishing a causal link. Consequently, loss of AID delays G1/S cell cycle transition and reduces proliferation. In addition, AID expression skews transcriptional programs towards ABC-type DLBCL in cell lines. In agreement, AID expression correlates with ABC-type gene expression in primary DLBCL patient samples. Moreover, AID overexpression resulted in increased IRF4 protein levels, and enhanced NF-{kappa}B activity, supporting AIDs role in reinforcing the ABC-type identity. Shared enrichment of the IRF4 co-factor BATF in AID-high tumors of both ABC- and GCB-subtypes points towards a common mechanism driving subtype skewing. These findings underscore a broader role for AID in DLBCL pathogenesis, establishing AID as a key regulator of transcriptional programs linked to cell cycle progression and DLBCL subtype.

cancer biology↗

bioRxiv2019

Targeting AKT elicits tumor suppressive functions of FOXO transcription factors and GSK3 kinase in Multiple Myeloma

The phosphatidylinositide-3 kinases (PI3K) and the downstream mediator AKT drive survival and proliferation of multiple myeloma (MM) cells and several AKT inhibitors are currently being tested in clinical trials for MM patients. AKT inhibition has pleiotropic effects, and the key aspects that determine therapeutic efficacy are not fully clear. Therefore, we investigated the antimyeloma mechanism(s) of AKT inhibition. Among the various downstream AKT targets are Forkhead box O (FOXO) transcription factors, and we demonstrate that they are crucial for changes in gene expression upon AKT inhibition. Based on gene expression profiling we defined an AKT-induced FOXO-dependent gene set that has prognostic significance in a large cohort of MM patients, where low FOXO activity correlates with inferior survival. We show that cell cycle exit and cell death of MM cells after AKT inhibition required FOXO. In addition, glycogen synthase kinase 3 (GSK3), a negatively regulated AKT substrate, proved to be pivotal to induce cell death and to inhibit cell cycle progression after AKT inhibition. Finally, we demonstrate that FOXO and GSK3 induced cell death by increasing the turnover of the myeloid cell leukemia 1 (MCL1) protein. In concordance, the AKT inhibitor MK2206 greatly sensitized MM cells for the MCL1 inhibitor S63845. Thus, our results indicate that FOXO and GSK3 are crucial mediators of the antimyeloma effects of AKT inhibition, and suggest combination therapies that may have therapeutic potential in MM.\n\nKEYPOINTSO_LIFOXO transcription factors and the GSK3 kinase are pivotal tumor suppressors downstream of AKT inhibition in MM cells.\nC_LIO_LIFOXO and GSK3 activation after AKT inhibition leads to a decrease in MCL1 levels in MM cells resulting in cell death.\nC_LI

cancer biology↗